EGFR and non-small cell lung carcinoma: In a phase 1/2 study that evaluated the third-generation EGFR TKI osimertinib (80 mg/day), none of the 12 enrolled patients with NSCLC harboring EGFR exon 20 insertion mutations experienced an objective response [28].